Table 2 Cox regression models for overall survival in all patients, in all NSCLC patients and in stage IV NSCLC patients,
From: Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer
study population (n = 164) | HRb | FWDa 95% CIc | pd |
|---|---|---|---|
Agee | 0.235 | ||
Sexf | 0.987 | ||
Histologyg | 0.099 | ||
Metastasish | 3.9 × 10−11 | ||
sTREM-1i | 1.48 | 1.06–2.06 | 0.020 |
Subpopulation A (n = 137) | HR b | FWD a 95% CI c | p d |
Agee | 0.058 | ||
Sexf | 0.816 | ||
sTREM-1i | 1.6 | 1.08–2.39 | 0.011 |
Stage | 4.9 × 10−11 | ||
1 vs. 2 | 1.8 | 0.61–5.17 | |
2 vs. 3 | 3.0 | 1.38–6.64 | |
3 vs. 4 | 8.3 | 3.81–18.01 | |
Histology | |||
ACj | 0.163 | ||
SCCk | 0.388 | ||
LCCl | 0.081 | ||
Subpopulation D (n = 75) | HR b | FWD a 95% CI c | p d |
Agee | 0.518 | ||
Sexf | 0.175 | ||
sTREM-1i | 1.94 | 1.17–3.2 | 0.008 |
Histology | |||
ACj | 0.193 | ||
SCCk | 0.706 | ||
LCCl | 0.137 | ||